TRVI (39) BRVE (47) ADRX (52) TRAX (33) ⌘ Pro Terminal →

Xeris Biopharma Holdings Inc. (XERS) — RQD Stock Rating Cockpit

$10.75 +1.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.75

Xeris Biopharma Holdings Inc. (XERS) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $1.96B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.75 (+0.00%)🧬 Disciplined Float (+0.24% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 9.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE+1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XERS)Realized 20D OHLCV Swing Band: ±10.4%

Deterministic 5-Pillar Attribution (62/100 Composite)

🔍 WHY XERS SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 9.8% FCF Margin ($28.6M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (19% of score)

20D Institutional Volume Accumulation (±10.4% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)

Disciplined Float (+0.24% YoY Shares) & executive Form 4 sales trim 9 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$10.48-1.6% Next Q

Q2 (-2Q)

Grade C$10.31-1.1% Next Q

Q3 (-1Q)

Grade C$10.20+5.4% Next Q

Current

Grade C$10.75+0.7% Hist 90D α

Trajectory: C- (54) → C (62)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the XERS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, XERS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+0.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.31) or 200D SMA ($7.50) invalidates the momentum regime and cuts Target Base ($10.94) toward Bear Floor ($8.53).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XERS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “XERS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 62%NO 38%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

6030 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.11>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE89% OF RANGE

L: $5$10.75H: $11

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (steady margins and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 23 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on XERS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (80)

16.0% ROIC with 42.0% gross margin and 1.46% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (60)

Altman-Z 2.11 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (57)

23/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like XERS

✓Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.

Bear Case: What Could Go Wrong

!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (XERS Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XERS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +75.37%▲ ASCENDING CHANNEL

2026-10-30O $10.81H $10.88L $10.52C $10.75VOL 1.55M

RES: $12.23SUP: $8.21SMA50: $9.31SMA200: $7.50

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XERS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XERS Butterfly Map → + Track XERS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +43.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XERS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XERS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XERS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XERS)

Health Care Rank #168 of 1016 ⚔️ TRVI vs XERS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XERS vs. TRVI, BRVE, ADRX, TRAX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Xeris Biopharma Holdings Inc. (XERS) ranks #168 by composite RQD confidence (62/100, grade C) and #267 by equity capitalization ($1.96B). Within this direct 5-issuer industry benchmark cohort, XERS leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XERS ACTIVE Xeris Biopharma Holdings Inc.	C	62/100	—	—	16.0%	+1.03%	$1.96B	Benchmark Subject
TRVI Trevi Therapeutics Inc.	D-	39/100	—	—	-23.7%	+2.15%	$1.97B	/trvi-vs-xers →
BRVE Braveheart Bio Inc.	D	47/100	—	—	—	-2.62%	$1.91B	/brve-vs-xers →
ADRX ADARx Pharmaceuticals Inc.	D+	52/100	—	—	—	-0.56%	$1.91B	/adrx-vs-xers →
TRAX First Tracks Biotherapeutics Inc.	E	33/100	—	—	-35.0%	-1.08%	$1.90B	/trax-vs-xers →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001867096

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xeris Biopharma Holdings Inc. (XERS) reported GAAP revenue of $291.8M (+43.7% vs. FY2024 revenue of $203.1M , and +78.0% cumulative change since FY2023) , GAAP net income of $554.0K, operating cash flow of $28.6M, and free cash flow of $28.6M (+177.4% YoY). On the balance sheet, XERS closed FY2025 with $383.5M in total assets against $220.3M in total debt (Altman Z-Score: 2.11, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$291.8M	$554.0K	$28.6M	$28.6M	$383.5M	$220.3M
FY2024 (FY)	2024-12-31	$203.1M	-$54.8M	-$37.0M	-$37.0M	$323.1M	$217.0M
FY2023 (FY)	2023-12-31	$163.9M	-$62.3M	-$47.0M	-$47.0M	—	—

3. XERS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Xeris Biopharma Holdings Inc. (NASDAQ: XERS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $10.75 (+1.03% 1D, market cap $1.96B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, XERS ranks #168 in composite RQD confidence.

How does XERS compare to TRVI and BRVE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XERS carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 16.0%. By comparison, TRVI (Trevi Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -23.7%, cap $1.97B) and BRVE (Braveheart Bio Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $1.91B). Among the 5-stock peer group, XERS leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XERS?

Per XERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001867096), Xeris Biopharma Holdings Inc. generated $291.8M in revenue (+43.7% YoY), $554.0K in net income, and $28.6M in free cash flow against $383.5M in total assets and $220.3M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XERS trading relative to its 50-day, 200-day, and 52-week technical levels?

XERS last traded at $10.75 (+1.03% on volume of 1,745,572 shares), positioning the stock +15.47% above its 50-day simple moving average ($9.31) and +43.33% above its 200-day simple moving average ($7.50). Across its 52-week range of $5.25 to $11.42, XERS sits at the 89.1% percentile with a 14-day RSI of 60.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.4% ($9.63 to $11.87).

XERS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell XERS stock right now?

Xeris Biopharma Holdings Inc. (XERS) currently earns a Roarable Rating of C (Hold — HOLD) with 62/100 RQD Confidence. Solid steady margins (16% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.

What is XERS's 12-month price target and RQD AI Jury consensus?

XERS's 12-month base price target is $10.94 (range $8.53 to $12.91), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: XERS RQD Cockpit XERS 12M Forecast XERS Earnings & Move XERS Dividends & DRIP XERS Insiders & 13F XERS Whale Options XERS Profit Sankey XERS News & Why